Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Medtronic (MDT) through the VizualStocks API.
Revenue of the Acute Care and Monitoring division under the issuer reporting composition. Earlier Respiratory, Gastrointestinal and Renal or Patient Monitoring and Respiratory Interventions aggregates are broader; explicit historical recasts excluding ventilators are used where reported.
acuteCareAndMonitoringRevenueIssuer-allocated Cardiovascular segment profit (called segment EBITA in earlier reports). Allocation definitions change over time, including corporate, stock-compensation and centralized-distribution costs beginning FY2026. Complete compatible source cohorts are retained when later three-segment recasts no longer disclose Diabetes separately; the measure is not a uniformly allocated GAAP segment operating-profit series.
cardiovascularOperatingProfitPeriod-over-period revenue growth for cardiovascular, excluding acquisition, divestiture and foreign-exchange effects as defined by the company.
cardiovascularOrganicRevenueGrowthNet sales from Medtronic's Cardiovascular reportable segment, spanning cardiac rhythm and ablation, coronary and peripheral vascular devices, heart valves and aortic therapies, cardiac surgery, and renal denervation. Diabetes and the separately reported Other businesses are outside this segment.
cardiovascularRevenueRevenue from Medtronic spine implants, bone-graft and biologic products, neurosurgical instruments, imaging and navigation systems, and robotic guidance for cranial and spine procedures. The division includes the AiBLE ecosystem and technologies such as StealthStation, O-arm and Mazor robotics.
cranialAndSpinalTechnologiesRevenuePeriod-over-period revenue growth for diabetes, excluding acquisition, divestiture and foreign-exchange effects as defined by the company.
diabetesOrganicRevenueGrowthRevenue from Medtronic's insulin pumps, continuous glucose-monitoring systems and recurring consumables for people with diabetes. After the MiniMed IPO, Medtronic's reported Diabetes revenue can differ from standalone MiniMed because of carve-out, standalone and transition-accounting bases.
diabetesRevenueIssuer-allocated MedicalSurgical segment profit (called segment EBITA in earlier reports). Allocation definitions change over time, including corporate, stock-compensation and centralized-distribution costs beginning FY2026. Complete compatible source cohorts are retained when later three-segment recasts no longer disclose Diabetes separately; the measure is not a uniformly allocated GAAP segment operating-profit series.
medicalSurgicalOperatingProfitPeriod-over-period revenue growth for medical surgical, excluding acquisition, divestiture and foreign-exchange effects as defined by the company.
medicalSurgicalOrganicRevenueGrowthNet sales from Medtronic's Medical Surgical segment, combining Surgical and Endoscopy with Acute Care and Monitoring. Products span stapling, vessel sealing, robotic and digital surgery, gastrointestinal diagnostics, patient monitoring and airway management from diagnosis through recovery.
medicalSurgicalRevenueRevenue from Medtronic spinal-cord and brain-stimulation systems, implantable drug-infusion pumps and interventional pain products. These therapies address chronic pain, movement disorders, epilepsy and severe spasticity rather than conventional spine implants or neurovascular devices.
neuromodulationRevenueIssuer-allocated Neuroscience segment profit (called segment EBITA in earlier reports). Allocation definitions change over time, including corporate, stock-compensation and centralized-distribution costs beginning FY2026. Complete compatible source cohorts are retained when later three-segment recasts no longer disclose Diabetes separately; the measure is not a uniformly allocated GAAP segment operating-profit series.
neuroscienceOperatingProfitPeriod-over-period revenue growth for neuroscience, excluding acquisition, divestiture and foreign-exchange effects as defined by the company.
neuroscienceOrganicRevenueGrowthNet sales from Medtronic's Neuroscience segment, combining Cranial and Spinal Technologies, Specialty Therapies and Neuromodulation. The portfolio spans spine surgery and enabling technology, stroke and ENT devices, pelvic-health therapies, neurostimulation and drug-delivery systems.
neuroscienceRevenueAdjustment bridging separately disclosed segment profits to consolidated GAAP operating profit. It includes items excluded from the selected issuer segment-profit allocation and, after separate Diabetes profit reporting ceased, the combined non-reportable-segment contribution. Supported quarterly arithmetic retains original source operands; annual values require a direct combined disclosure.
otherOperatingProfitReconciliationIssuer Other adjustments reconciling reported segment and other operating revenue to consolidated revenue, including Italian payback adjustments when reported. This is separate from the Other operating segment and can be negative.
otherRevenueResidual used to reconcile Medtronic's geographic revenue components to consolidated revenue. It is zero throughout the available history and does not represent a separately disclosed geographic market.
otherRevenueByGeographyProfit or loss of the separately reported Other operating segment, excluding Diabetes. The combined Other operating segments profit after Diabetes reporting ceased in FY2026 Q4 is a different population and is not substituted.
otherSegmentOperatingProfitRevenue from the issuer Other operating segment, including exited or divested businesses and ongoing manufacturing or transition arrangements. Excludes separately disclosed Diabetes revenue and the separate Other adjustments reconciliation; historical issuer reclassifications are used where explicitly reported.
otherSegmentRevenueRevenue from Medtronic's Neurovascular, Ear, Nose and Throat, and Pelvic Health businesses. Products include stroke and brain-aneurysm devices, ENT surgical and navigation systems, hearing-restoration products, and therapies for overactive bladder and urinary retention.
specialtyTherapiesRevenueRevenue of the Surgical and Endoscopy division, including the Surgical and Gastrointestinal presentation under the same reclassified composition. Earlier Surgical Innovations revenue alone excludes the subsequently transferred Gastrointestinal business and is not equivalent.
surgicalAndEndoscopyRevenueMedtronic net sales outside the United States and U.S. territories across all product businesses. The boundary is based on the company's U.S.-versus-international reporting split, not Medtronic's Irish legal domicile.
totalInternationalRevenuePeriod-over-period revenue growth for all reportable activities, excluding acquisition, divestiture and foreign-exchange effects as defined by the company.
totalOrganicRevenueGrowthMedtronic net sales in the United States and U.S. territories across Cardiovascular, Neuroscience, Medical Surgical, Diabetes and Other businesses. This is a geographic view of consolidated revenue rather than a separate operating segment.
unitedStatesRevenueHistorical revenue through fiscal 2026 from pacemakers, implantable monitors, defibrillators, cardiac resynchronization and ablation products, and related cardiac-rhythm services. Starting in fiscal 2027, Medtronic replaced this division with Electrophysiology Therapies; that new division's revenue is not a continuation of this series.
cardiacRhythmAndHeartFailureRevenueHistorical revenue through fiscal 2026 from coronary and peripheral stents, balloons, renal-denervation systems, endovascular grafts and other vascular therapies. Starting in fiscal 2027, Medtronic redistributed these businesses across Interventional Cardiology Therapies and Peripheral Vascular Health, so the replacement divisions are not continuations of this series.
coronaryAndPeripheralVascularRevenueIssuer-allocated Diabetes segment profit (called segment EBITA in earlier reports). Allocation definitions change over time, including corporate, stock-compensation and centralized-distribution costs beginning FY2026. Complete compatible source cohorts are retained when later three-segment recasts no longer disclose Diabetes separately; the measure is not a uniformly allocated GAAP segment operating-profit series.
diabetesOperatingProfitHistorical Medtronic revenue from emerging-market countries through fiscal 2024. Beginning in fiscal 2025, Medtronic combined this geography with Non-U.S. Developed Markets into a single International revenue category, so later zeros mean not separately reported.
emergingMarketsRevenueHistorical Medtronic revenue from developed markets outside the United States through fiscal 2024. Beginning in fiscal 2025, Medtronic combined this geography with Emerging Markets into a single International revenue category, so later zeros mean not separately reported.
nonUnitedStatesDevelopedMarketsRevenueHistorical revenue through fiscal 2026 from transcatheter and surgical heart valves, aortic stent grafts and related structural-heart and cardiac-surgery therapies. Starting in fiscal 2027, Medtronic redistributed these businesses across Interventional Cardiology Therapies and CardioVascular Surgery, so the replacement divisions are not continuations of this series.
structuralHeartAndAorticRevenue